Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1172 - Development and validation of a nomogram for predicting survival in patients with operable triple negative breast cancer (59P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Jieqiong Liu

Citation

Annals of Oncology (2017) 28 (suppl_10): x16-x24. 10.1093/annonc/mdx655

Authors

J. Liu1, Y. Yang1, H. Deng1, C. Tan1, W. Wei2, E. Zhou3, Q. Liu1

Author affiliations

  • 1 Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 510120 - Guangzhou/CN
  • 2 Department Of Breast And Thyroid Surgery, Peking University Shenzhen Hospital, Shenzhen/CN
  • 3 Department Of Breast Surgery, the Second Xiangya Hospital, Changsha/CN
More

Resources

Abstract 1172

Background

Personalized nomograms for predicting survival outcomes of operable triple negative breast cancer (TNBC) are scarce. The aim of this study is to develop and validate an effective nomogram to predict disease-free and overall survival for women with early TNBC in China.

Methods

The nomogram was based on a retrospectively analysis on 296 invasive operable TNBC women treated at Sun Yat-sen Memorial Hospital from 2002 to 2014. The predictive accuracy and discriminative ability of nomogram were determined by concordance index (C-index) and calibration curve and compared with the seventh American Joint Committee on Cancer (AJCC) staging system. The model was subjected to bootstrap internal validation and to external validation with a separate cohort of 108 patients from the second Xiangya Hospital and Peking University Shenzhen Hospital.

Results

On multivariate analysis of the training cohort, independent factors for outcomes were stromal tumor-infiltrating lymphocytes (TILs), tumor size, node status, and Ki67 index, which were selected into the nomogram. The calibration curves for probability of disease-free survival (DFS) and overall survival (OS) showed optimal agreement between nomogram prediction and actual observation. The C-index of the nomogram was higher than that of the seventh AJCC staging system for predicting DFS (training cohort: 0.730 vs 0.668, respectively, P = 0.026; validation cohort: 0.750 vs 0.676, respectively, P = 0.051) and OS (training cohort: 0.745 vs 0.676, respectively, P = 0.049; validation cohort: 0.810 vs 0.659, respectively, P = 0.278). The stratification into different risk groups allowed significant distinction between survival curves within respective TNM categories.

Conclusions

We developed a novel well-calibrated nomogram that can provide individual prediction of DFS and OS for operable TNBC based on Chinese breast cancer data. This practical prognostic model can help clinicians in decision making and surveillance recommendation.

Clinical trial identification

Legal entity responsible for the study

Jieqiong Liu

Funding

The National Natural Science Foundation of China

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings